Natural Killer (NK) Cells: Pushing the Next Wave of Immuno-oncology Therapies

3:00 PM - 4:00 PM, Wednesday, June 10, 2020 ・ Room 6C
The field of immuno-oncology has grown exponentially, leading to a host of new therapeutics being developed to recruit the immune system to fight cancer. While T cell-based therapies (BiTES and CARTs) have advanced the farthest, a new wave of drugs that recruit the innate immune system also hold remarkable promise to treat cancer patients with long-term success, but with less side effects. From next generation, off-the-shelf NK cell therapies to Fc-enhanced mAbs and fully synthetic, bispecific Antibody Recruiting Molecules (ARMs) that recruit NK cells and macrophages to rapidly destroy cancer cells, these new drugs could potentially change the game when it comes to engaging the immune system to kill tumors. Panelists will address the opportunities and challenges for these next-generation immuno-oncology drugs.
Moderator
photo
Associate Principal
Cello Health BioConsulting (previously Defined Health)
Speakers
photo
CEO
Celularity
photo
CEO
Kleo Pharmaceuticals, Inc.